{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:08:18Z","timestamp":1795043298931,"version":"4.10.2"},"reference-count":75,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI156922"],"award-info":[{"award-number":["AI156922"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL086889"],"award-info":[{"award-number":["HL086889"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA245483"],"award-info":[{"award-number":["K08CA245483"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Bone marrow vascular endothelial cells (BM EC) regulate multiple myeloma pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating multiple myeloma. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote multiple myeloma growth, revealing overexpression of the receptor tyrosine kinases, EPHB1 and EPHB4, in multiple myeloma\u2013supportive ECs. Expression of ephrin B2 (EFNB2), the binding partner for EPHB1 and EPHB4, was significantly increased in multiple myeloma cells. Silencing EPHB1 or EPHB4 in ECs suppressed multiple myeloma growth in coculture. Similarly, loss of EFNB2 in multiple myeloma cells blocked multiple myeloma proliferation and survival in vitro, abrogated multiple myeloma engraftment in immune-deficient mice, and increased multiple myeloma sensitivity to chemotherapy. Administration of an EFNB2-targeted single-chain variable fragment also suppressed multiple myeloma growth in vivo. In contrast, overexpression of EFNB2 in multiple myeloma cells increased STAT5 activation, increased multiple myeloma cell survival and proliferation, and decreased multiple myeloma sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in multiple myeloma cells increased multiple myeloma cell death and sensitivity to chemotherapy and abolished multiple myeloma growth in vivo. Complementary analysis of multiple myeloma patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls multiple myeloma pathogenesis and can be therapeutically targeted to improve multiple myeloma outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Ephrin B2 reverse signaling mediated by endothelial cells directly regulates multiple myeloma progression and treatment resistance, which can be overcome through targeted inhibition of ephrin B2 to abolish myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-23-1950","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T12:40:25Z","timestamp":1705495225000},"page":"919-934","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis"],"prefix":"10.1158","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-462X","authenticated-orcid":false,"given":"Joshua P.","family":"Sasine","sequence":"first","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"2Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California."},{"name":"3Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"4Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5117-4370","authenticated-orcid":false,"given":"Natalia Y.","family":"Kozlova","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"2Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4368-3899","authenticated-orcid":false,"given":"Lisa","family":"Valicente","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"2Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0234-1689","authenticated-orcid":false,"given":"Jennifer","family":"Dukov","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"2Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-9281","authenticated-orcid":false,"given":"Dana H.","family":"Tran","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"2Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-6371","authenticated-orcid":false,"given":"Heather A.","family":"Himburg","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-0627","authenticated-orcid":false,"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3345-9854","authenticated-orcid":false,"given":"Sarah","family":"Khorsandi","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9006-2519","authenticated-orcid":false,"given":"Aldi","family":"Chan","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1187-7620","authenticated-orcid":false,"given":"Samantha","family":"Grohe","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7545-0992","authenticated-orcid":false,"given":"Michelle","family":"Li","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Medicine, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9959-3146","authenticated-orcid":false,"given":"Jenny","family":"Kan","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Medicine, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2301-0562","authenticated-orcid":false,"given":"Mary E.","family":"Sehl","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Medicine, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-3467","authenticated-orcid":false,"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Medicine, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-2517","authenticated-orcid":false,"given":"Bryanna","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9689-8382","authenticated-orcid":false,"given":"Brijesh Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"7Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1496-4436","authenticated-orcid":false,"given":"Ritchie","family":"Ho","sequence":"additional","affiliation":[{"name":"7Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-8441","authenticated-orcid":false,"given":"Peibin","family":"Yue","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-4848","authenticated-orcid":false,"given":"Elena B.","family":"Pasquale","sequence":"additional","affiliation":[{"name":"8Sanford Burnham Prebys Medical Discovery Institute, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8841-0527","authenticated-orcid":false,"given":"John P.","family":"Chute","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"2Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California."},{"name":"3Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California."},{"name":"4Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"2024031507075832700_bib1","article-title":"Surveillance Epidemiology and End Results (SEER) Program (https:\/\/seer.cancer.gov\/) SEER*Stat Database: Populations - Total U.S. (1969\u20132014) &lt;csingle ages to 85+, Katrina\/Rita Adjustment&gt;- linked to county attributes - Total U.S., 1969\u20132014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch","author":"Surveillance Epidemiology and End Results (SEER) Program","year":"2015"},{"key":"2024031507075832700_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2024031507075832700_bib3","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"2024031507075832700_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.ircmb.2014.10.004","article-title":"Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis","volume":"314","author":"Ribatti","year":"2015","journal-title":"Int Rev Cell Mol Biol"},{"key":"2024031507075832700_bib5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"key":"2024031507075832700_bib6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nm.3867","article-title":"The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells","volume":"21","author":"Zhu","year":"2015","journal-title":"Nat Med"},{"key":"2024031507075832700_bib7","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-14-0847","article-title":"A HGF\/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target","volume":"20","author":"Ferrucci","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2024031507075832700_bib8","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"2024031507075832700_bib9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/leu.2013.254","article-title":"Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies","volume":"28","author":"Frassanito","year":"2014","journal-title":"Leukemia"},{"key":"2024031507075832700_bib10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2174\/156800912802429346","article-title":"Antiangiogenic therapeutic approaches in multiple myeloma","volume":"12","author":"Ribatti","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"2024031507075832700_bib11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/0008-5472.CAN-15-1637","article-title":"Chromogranin a is preferentially cleaved into proangiogenic peptides in the bone marrow of multiple myeloma patients","volume":"76","author":"Bianco","year":"2016","journal-title":"Cancer Res"},{"key":"2024031507075832700_bib12","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/leu.2013.76","article-title":"The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis","volume":"27","author":"Kocemba","year":"2013","journal-title":"Leukemia"},{"key":"2024031507075832700_bib13","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/sj.leu.2403076","article-title":"Vascular endothelial growth factor and its receptors in multiple myeloma","volume":"17","author":"Ria","year":"2003","journal-title":"Leukemia"},{"key":"2024031507075832700_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2016.3","article-title":"Targeting vasculogenesis to prevent progression in multiple myeloma","volume":"30","author":"Moschetta","year":"2016","journal-title":"Leukemia"},{"key":"2024031507075832700_bib15","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"key":"2024031507075832700_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"2024031507075832700_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrm.2015.16","article-title":"Mechanisms of ephrin-Eph signalling in development, physiology and disease","volume":"17","author":"Kania","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2024031507075832700_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0092-8674(00)81436-1","article-title":"Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4","volume":"93","author":"Wang","year":"1998","journal-title":"Cell"},{"key":"2024031507075832700_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1101\/gad.13.3.295","article-title":"Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial\/venous domains, vascular morphogenesis, and sprouting angiogenesis","volume":"13","author":"Adams","year":"1999","journal-title":"Genes Dev"},{"key":"2024031507075832700_bib20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1073\/pnas.1324215111","article-title":"EphB receptor forward signaling regulates area-specific reciprocal thalamic and cortical axon pathfinding","volume":"111","author":"Robichaux","year":"2014","journal-title":"Proc Nat Acad Sci USA"},{"key":"2024031507075832700_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nn2033","article-title":"Ephrin-B reverse signaling promotes structural and functional synaptic maturation in vivo","volume":"11","author":"Lim","year":"2008","journal-title":"Nat Neurosci"},{"key":"2024031507075832700_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0092-8674(01)00297-5","article-title":"Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction","volume":"105","author":"Lu","year":"2001","journal-title":"Cell"},{"key":"2024031507075832700_bib23","doi-asserted-by":"crossref","first-page":"e157694","DOI":"10.1172\/jci.insight.157694","article-title":"Notch-mediated Ephrin signaling disrupts islet architecture and beta cell function","volume":"7","author":"Bartolome","year":"2022","journal-title":"JCI Insight"},{"key":"2024031507075832700_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature08995","article-title":"Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis","volume":"465","author":"Sawamiphak","year":"2010","journal-title":"Nature"},{"key":"2024031507075832700_bib25","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1172\/JCI87848","article-title":"Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow","volume":"126","author":"Kwak","year":"2016","journal-title":"J Clin Invest"},{"key":"2024031507075832700_bib26","doi-asserted-by":"crossref","first-page":"7390104","DOI":"10.1155\/2018\/7390104","article-title":"Differential expression patterns of eph receptors and ephrin ligands in human cancers","volume":"2018","author":"Kou","year":"2018","journal-title":"Biomed Res Int"},{"key":"2024031507075832700_bib27","first-page":"613","article-title":"Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival","volume":"9","author":"Kinch","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2024031507075832700_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/0008-5472.CAN-15-0717","article-title":"EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer","volume":"76","author":"Amato","year":"2016","journal-title":"Cancer Res"},{"key":"2024031507075832700_bib29","first-page":"2301","article-title":"EphA2 overexpression causes tumorigenesis of mammary epithelial cells","volume":"61","author":"Zelinski","year":"2001","journal-title":"Cancer Res"},{"key":"2024031507075832700_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/0008-5472.CAN-09-1845","article-title":"Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy","volume":"70","author":"Zhuang","year":"2010","journal-title":"Cancer Res"},{"key":"2024031507075832700_bib31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/mc.22574","article-title":"Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors","volume":"56","author":"Oweida","year":"2017","journal-title":"Mol Carcinog"},{"key":"2024031507075832700_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nature13547","article-title":"Reprogramming human endothelial cells to haematopoietic cells requires vascular induction","volume":"511","author":"Sandler","year":"2014","journal-title":"Nature"},{"key":"2024031507075832700_bib33","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1073\/pnas.0401381101","article-title":"Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth","volume":"101","author":"Noren","year":"2004","journal-title":"Proc Nat Acad Sci USA"},{"key":"2024031507075832700_bib34","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"key":"2024031507075832700_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2024031507075832700_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kramer","year":"2014","journal-title":"Bioinformatics"},{"key":"2024031507075832700_bib37","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2024031507075832700_bib38","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-20-2931","article-title":"Chromatin accessibility identifies regulatory elements predictive of gene expression and disease outcome in multiple myeloma","volume":"27","author":"Barwick","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024031507075832700_bib39","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"2024031507075832700_bib40","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"2024031507075832700_bib41","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.2112","article-title":"Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity","volume":"16","author":"McMillin","year":"2010","journal-title":"Nat Med"},{"key":"2024031507075832700_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"2024031507075832700_bib43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"2024031507075832700_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2024031507075832700_bib45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1101\/gad.1630408","article-title":"Eph\/ephrin signaling: networks","volume":"22","author":"Arvanitis","year":"2008","journal-title":"Genes Dev"},{"key":"2024031507075832700_bib46","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1182\/blood-2011-09-380006","article-title":"Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth","volume":"119","author":"Abengozar","year":"2012","journal-title":"Blood"},{"key":"2024031507075832700_bib47","doi-asserted-by":"crossref","first-page":"17305","DOI":"10.1073\/pnas.0702337104","article-title":"ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3","volume":"104","author":"Bong","year":"2007","journal-title":"Proc Nat Acad Sci U S A"},{"key":"2024031507075832700_bib48","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.1038\/ncomms7576","article-title":"EphrinB2 controls vessel pruning through STAT1-JNK3 signalling","volume":"6","author":"Salvucci","year":"2015","journal-title":"Nat Commun"},{"key":"2024031507075832700_bib49","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1038\/s41467-022-31124-7","article-title":"EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment","volume":"13","author":"Bhatia","year":"2022","journal-title":"Nat Commun"},{"key":"2024031507075832700_bib50","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.117.311045","article-title":"EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-beta\/Smad3 signaling","volume":"121","author":"Su","year":"2017","journal-title":"Circ Res"},{"key":"2024031507075832700_bib51","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2003-06-2151","article-title":"Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis","volume":"103","author":"Bharti","year":"2004","journal-title":"Blood"},{"key":"2024031507075832700_bib52","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2003-06-2007","article-title":"SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak\/STAT pathway","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"key":"2024031507075832700_bib53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1593\/neo.91192","article-title":"INCB16562, a JAK1\/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support","volume":"12","author":"Li","year":"2010","journal-title":"Neoplasia"},{"key":"2024031507075832700_bib54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/leu.2010.289","article-title":"The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival","volume":"25","author":"Scuto","year":"2011","journal-title":"Leukemia"},{"key":"2024031507075832700_bib55","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2011.175","article-title":"The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells","volume":"25","author":"Monaghan","year":"2011","journal-title":"Leukemia"},{"key":"2024031507075832700_bib56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat Methods"},{"key":"2024031507075832700_bib57","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3389\/fimmu.2019.01473","article-title":"Emerging roles for eph receptors and ephrin ligands in immunity","volume":"10","author":"Darling","year":"2019","journal-title":"Front Immunol"},{"key":"2024031507075832700_bib58","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ydbio.2004.03.027","article-title":"Bidirectional signaling mediated by ephrin-B2 and EphB2 controls urorectal development","volume":"271","author":"Dravis","year":"2004","journal-title":"Dev Biol"},{"key":"2024031507075832700_bib59","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nn.2254","article-title":"Ephrin-B3 reverse signaling through Grb4 and cytoskeletal regulators mediates axon pruning","volume":"12","author":"Xu","year":"2009","journal-title":"Nat Neurosci"},{"key":"2024031507075832700_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/35093123","article-title":"The SH2\/SH3 adaptor Grb4 transduces B-ephrin reverse signals","volume":"413","author":"Cowan","year":"2001","journal-title":"Nature"},{"key":"2024031507075832700_bib61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14728222.2020.1745187","article-title":"Ephrin or not? Six tough questions on Eph targeting","volume":"24","author":"Giorgio","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"2024031507075832700_bib62","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbapap.2014.07.002","article-title":"Promiscuous and specific recognition among ephrins and Eph receptors","volume":"1844","author":"Dai","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"2024031507075832700_bib63","first-page":"1197","article-title":"Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells","volume":"27","author":"Meyer","year":"2005","journal-title":"Int J Oncol"},{"key":"2024031507075832700_bib64","doi-asserted-by":"crossref","first-page":"8492","DOI":"10.1158\/0008-5472.CAN-05-4211","article-title":"Ephrin-B3 ligand promotes glioma invasion through activation of Rac1","volume":"66","author":"Nakada","year":"2006","journal-title":"Cancer Res"},{"key":"2024031507075832700_bib65","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood-2009-01-201954","article-title":"The ephrinB2\/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth","volume":"114","author":"Pennisi","year":"2009","journal-title":"Blood"},{"key":"2024031507075832700_bib66","doi-asserted-by":"crossref","first-page":"34298","DOI":"10.18632\/oncotarget.16100","article-title":"Epha3 acts as proangiogenic factor in multiple myeloma","volume":"8","author":"Caivano","year":"2017","journal-title":"Oncotarget"},{"key":"2024031507075832700_bib67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s13402-017-0338-4","article-title":"EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells","volume":"40","author":"La Rocca","year":"2017","journal-title":"Cell Oncol (Dordr)"},{"key":"2024031507075832700_bib68","doi-asserted-by":"crossref","first-page":"1010428317694298","DOI":"10.1177\/1010428317694298","article-title":"EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma","volume":"39","author":"Ding","year":"2017","journal-title":"Tumour Biol"},{"key":"2024031507075832700_bib69","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/cdd.2015.133","article-title":"DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53","volume":"23","author":"Alam","year":"2016","journal-title":"Cell Death Differ"},{"key":"2024031507075832700_bib70","doi-asserted-by":"crossref","first-page":"e0188965","DOI":"10.1371\/journal.pone.0188965","article-title":"Ephrin-B2 reverse signaling regulates progression and lymph node metastasis of oral squamous cell carcinoma","volume":"12","author":"Sasabe","year":"2017","journal-title":"PLoS One"},{"key":"2024031507075832700_bib71","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/ijc.24849","article-title":"The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion","volume":"126","author":"Nakada","year":"2010","journal-title":"Int J Cancer"},{"key":"2024031507075832700_bib72","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jb\/mvv042","article-title":"Eph\/ephrin reverse signalling induces axonal retraction through RhoA\/ROCK pathway","volume":"158","author":"Takeuchi","year":"2015","journal-title":"J Biochem"},{"key":"2024031507075832700_bib73","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood-2006-05-023341","article-title":"EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling","volume":"108","author":"Salvucci","year":"2006","journal-title":"Blood"},{"key":"2024031507075832700_bib74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10456-010-9183-z","article-title":"The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis","volume":"13","author":"Martiny-Baron","year":"2010","journal-title":"Angiogenesis"},{"key":"2024031507075832700_bib75","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood-2005-04-1655","article-title":"The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth","volume":"107","author":"Kertesz","year":"2006","journal-title":"Blood"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-23-1950\/3404990\/can-23-1950.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/6\/919\/3421402\/919.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/6\/919\/3421402\/919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T03:08:59Z","timestamp":1710472139000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/84\/6\/919\/735003\/Inhibition-of-Ephrin-B2-Reverse-Signaling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":75,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,17]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-23-1950","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.25415573","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.25415573.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.7122911","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.7122911.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]}}}